Humacyte, Inc. (HUMA) stock
HUMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.59+0.00 (+0.29%)
Close on Nov 11, 2026Market cap $164.37MP/E –Yield –
Humacyte profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Humacyte's profit margin for the twelve months ending Sep 30, 2026 was -3955.1%. For fiscal 2025 it was -2003.6%.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -2003.6% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -1511.5% | +813.9 |
| Q2 FY2026 | Jun 30, 2026 | -9064.5% | +3446.4 |
| Q1 FY2026 | Mar 31, 2026 | -3559.4% | −11129.8 |
| Q4 FY2025 | Dec 31, 2025 | -5311.3% | +7785.3 |
| Q3 FY2025 | Sep 30, 2025 | -2325.4% | −382.3 |
| Q2 FY2025 | Jun 30, 2025 | -12511.0% | – |
| Q1 FY2025 | Mar 31, 2025 | 7570.4% | – |
| Q3 FY2021 | Sep 30, 2021 | -13096.7% | – |
| Q3 FY2020 | Sep 30, 2020 | -1943.1% | – |
See a number that looks wrong?